Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Respiratory, Type 2 Inflammation & Fibrosis Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for IL-33 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | IL-33 Full-Length / Mature Form Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed. |
View IL-33 Products |
| Receptor | ST2 (IL1RL1) ECD-Fc Fusion Protein High purity (>95%). Sequence Verified. For binding competition assays. |
View ST2 Products |
| Gene Delivery | IL-33 Promise-ORF / Lentivirus Premade Particles Full-length ORF for stable overexpression cell lines. Titer >1E8 TU/ml. |
View IL-33 Products |
| Benchmark Ab | Anti-IL-33 (Itepekimab/Astegolimab/Etokimab Biosimilar Sequences) Recombinant positive control for blocking assays. Sequence Verified. |
View IL-33 Products |
| Validator | IL-33 siRNA Set (3 pre-designed sequences) For knockdown verification in primary cells. |
View IL-33 Products |
| Pathway Partner | TSLP Epithelial alarmin synergist; critical for type 2 inflammation combination studies. |
View TSLP Products |
| Downstream Mediator | IL-13 Type 2 cytokine downstream of IL-33 signaling; for combination therapy evaluation. |
View IL-13 Products |
TarMart Technical Advantages for Key Assay Challenges
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High-Affinity Blockade Validation (pM range) | Sequence Verified proteins with theoretical MW confirmation; suitable for SPR/BLI kinetic analysis |
| Cross-species Cyno/Mouse Evaluation | Human/Mouse/Cyno ortholog proteins available with >95% purity; sequence identity verified by mass spec |
| IL-1 Family Selectivity Screening | Homolog panel (IL-1α, IL-1β, IL-18, IL-36) strictly verified by mass spec for off-target binding exclusion |
| Cell-Based Signaling Inhibition | ST2/IL-1RAcP co-expression lentivirus available for reporter assay construction |
| Lack of Clinical Controls | Benchmark Antibodies (Itepekimab/Etokimab biosimilar sequences) included for assay standardization |
| False Positive Elimination | Validated siRNA included for specificity confirmation in loss-of-function studies |
Live IL-33 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for IL-33 therapeutics is intensifying, with major players such as Regeneron/Sanofi (Itepekimab), GSK (Astegolimab), Roche/Genentech, and AnaptysBio (Etokimab) advancing first-generation monoclonal antibodies into Phase 3 for severe asthma and COPD. As the field matures, differentiation is shifting from simple target blockade to epitope-specific inhibition that preserves beneficial IL-33 signaling while blocking pathogenic alarms. The next wave of R&D targets combination approaches with TSLP or IL-25 blockade and broad-spectrum epithelial-derived cytokine blockades, as well as fibrotic indications (IPF/liver fibrosis) where IL-33 drives tissue remodeling. Specialized atopic dermatitis and chronic rhinosinusitis with nasal polyps (CRSwNP) are also key indications.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocker) | Regeneron, Sanofi, AnaptysBio, GSK, Roche | Severe Asthma, COPD, CRSwNP | High-affinity SPR validation (Need pM-grade purified antigen) |
| Bispecific (TSLP x IL-33) | Emerging Biotechs | Severe Atopic Dermatitis | Heterodimer specificity (Need both antigens for ternary complex) |
| Soluble Receptor (Decoy) | Preclinical Academia | Fibrosis, EoE | ST2 binding competition assays (Need high-avidity ST2-ECD) |
| Small Molecule (Processing Inhibitor) | Early Discovery | Inflammatory Bowel Disease | Enzymatic activity assays (Need mature IL-33 forms) |